Almost all patients with bronchiectasis ex-modern chest physiotherapy were evaluated in a randomised study 10 of eight patients with pectorate sputum intermittently or daily. The sputum ranges from mucoid to purulent and stable bronchiectasis. Both nebulised treatments significantly increased the yield of exfrom scanty to copious. Patients with bronchiectasis have a number of other symptoms -pectorated fluid/mucus by a small amount, similar to the weight of the nebulised solution some are breathless with impaired lung function, usually predominantly an obstructive (only a 25% increase in the expectorated weight compared with physiotherapy alone). Interestventilatory defect, and asthma is frequent with an incidence of 28% (10 of 36) and 39% (nine ingly, nebulised terbutaline also increased the radioaerosol clearance rate in patients with of 23) having been reported in studies from Ireland 1 and England.
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Almost all patients with bronchiectasis ex-modern chest physiotherapy were evaluated in a randomised study 10 of eight patients with pectorate sputum intermittently or daily. The sputum ranges from mucoid to purulent and stable bronchiectasis. Both nebulised treatments significantly increased the yield of exfrom scanty to copious. Patients with bronchiectasis have a number of other symptoms -pectorated fluid/mucus by a small amount, similar to the weight of the nebulised solution some are breathless with impaired lung function, usually predominantly an obstructive (only a 25% increase in the expectorated weight compared with physiotherapy alone). Interestventilatory defect, and asthma is frequent with an incidence of 28% (10 of 36) and 39% (nine ingly, nebulised terbutaline also increased the radioaerosol clearance rate in patients with of 23) having been reported in studies from Ireland 1 and England. 2 Bronchial hyper-stable bronchiectasis. 8 Nebulised water 11 combined with physiotherapy resulted in an inreactivity to histamine 3 and methacholine 4 reported in 48% and 69% of patients is of un-crease in the amount of sputum expectorated and the total lung radiolabel clearance rate that certain significance in the presence of bronchi damaged by the primary disease process. In was similar to physiotherapy alone in a group of seven patients with bronchiectasis and no addition to local symptoms, patients with daily purulent sputum expectoration have systemic evidence of asthma.
Hypertonic saline (7.1%) significantly insymptoms such as malaise and tiredness both during and between acute exacerbations. 2 creased the weight of sputum produced and the whole lung radioaerosol clearance rate in Patients with bronchiectasis are at risk of disease progression. Forced expiratory volume 11 patients with chronic bronchitis. 12 In the same study the mucolytic agent, 2-mercaptoin one second (FEV 1 ) declined by >50 ml/ year in 80% of a group of 71 patients 5 and ethane sulphonate, had similar effects to hypertonic saline, although they were not sigradiographs had deteriorated in 18% of a group of 84 patients by the time of tertiary referral. 6 nificantly different from the control studies.
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There are no published studies on the use of Daily purulent sputum expectoration, indicative of a significant host inflammatory re-N-acetylcysteine in patients with bronchiectasis without cystic fibrosis. Sixty patients with stable sponse, 7 is likely to be an important risk factor for progression, although this is unproven. purulent bronchiectasis treated for two weeks with nebulised rhDNase showed no improvement in FEV 1 or sputum production in a double blind placebo controlled study.
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Indications for nebulisers in
The clinical importance of these observations bronchiectasis on mucus clearance is unknown. Few studies have been published on the use of nebulisers in bronchiectasis. The possible indications for nebulisers are (1) reversal of airways obstruction with bronchodilators in      patients with and without asthma, (2) im-    provement of mucus clearance, and (3) re-The objective of nebulised antimicrobial therduction of the microbial load in the bronchial apy in patients with bronchiectasis is to reduce tree.
the colonising microbial load in the lungs, improve symptoms, and prevent progression of the disease. Nebulised antimicrobial agents are usually prescribed for control of background     symptoms and for the reduction of severity or  prevention of acute exacerbations rather than No studies have been identified that were defor treatment of acute exacerbations. signed to evaluate the use of bronchodilator drugs for reversal of airways obstruction in patients with bronchiectasis. At present it is therefore appropriate to follow guidelines for Methodology patients with asthma 8 and chronic obstructive Evaluation of the effectiveness of nebulised pulmonary disease 9 without bronchiectasis (see antimicrobial agents in bronchiectasis should also paper by O'Driscoll on pp S49-52). Those include assessment of sputum character and patients prescribed nebulised antibiotics may volume.
14 The 24 hour volume of sputum require nebulised bronchodilators beforehand should be estimated from the history or, pre-
Dewsbury and District
(see paper by Webb and Dodd on pp S69-71). of terbutaline and 0.9% saline as adjuncts to the 24 hour volume of purulent sputum. The group.bmj.com on November 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from volume of purulent sputum was a better dis-cephalosporins have been prescribed for individual patients in recent years. Controlled criminator than sputum elastase levels for separating the antibiotic treated group from the studies of efficacy are long overdue. placebo group in a study of long term higher dose amoxycillin (3 g twice daily for seven months). 2 The erythrocyte sedimentation rate Recommendations for the use of nebulised antibiotics in bronchiectasis and white blood count are inconsistently raised in patients with purulent bronchiectasis be-Long term nebulised antibiotics should be considered when background symptoms, severity tween exacerbations 2 with no obvious correlation to purulent sputum volume. Serial of acute exacerbations, or risk of progression warrant them, provided that antibiotics by quantitative sputum bacterial culture 14 is a possible way of monitoring the response to nebu-other routes combined with regular postural drainage have been found unsuccessful, unlised antibiotics. However, no recognised pathogens were isolated in eight of 36 patients satisfactory, or not tolerated. Nebulised antibiotics should usually be used as an adjunct to with purulent bronchiectasis despite extensive and repeated culture on selective and non-regular home postural drainage and courses of oral or intravenous antibiotics for acute exselective media.
2 Lung function seems less likely to be reduced by the presence of purulent acerbations. sputum or its production in patients with bronchiectasis without cystic fibrosis than in patients with cystic fibrosis. Prolonged higher dose oral    Sputum culture may not reveal the particular amoxycillin (3 g twice daily) reduced the volume of purulent sputum in a double blind bacteria responsible for triggering the host inflammatory response. The presence of Pseudoplacebo controlled study but did not alter lung function.
2 Data on nebulised antibiotics in monas aeruginosa makes response to nonantipseudomonal antibiotics less likely 2 and patients with cystic fibrosis may not be applicable to other patients with bronchiectasis. should encourage use of nebulised antipseudomonal antibiotics analogous to their In addition, quality of life between exacerbations and severity of exacerbations usage in patients with cystic fibrosis with similar drugs and dosages (see paper on pp S69-71). should be evaluated.
Nebulised gentamicin (80 mg twice daily, each dose diluted with 0.9% saline to a total volume of 4 ml, unlicensed indication) is presently the  author's preferred choice. In addition, nebuSputum volume and purulence decreased and lised amoxycillin (500 mg twice daily diluted peak expiratory flow rate (PEFR) improved in 3-5 ml sterile water; unlicensed indication) during prolonged treatment with nebulised is worth considering in patients intolerant of amoxycillin 500 mg (intravenous preparation oral amoxycillin as a result of gastrointestinal diluted in 5 ml sterile water, unlicensed in-side effects or vaginal candidiasis. dication) twice daily in an open study 15 of six patients whose daily purulent sputum expectoration had failed to improve with oral   higher dose amoxycillin (3 g twice daily). These Antibiotics require either a breath controlled improvements occurred despite culture of ap-open vent nebuliser such as the Ventstream parently resistant organisms.
(Medic-Aid Ltd) with a standard compressor Prolonged nebulised antifungal therapy with or a high powered compressor with a standard natamycin was unhelpful in a double blind nebuliser (see paper by Webb and Dodd on placebo controlled study 16 of patients with al-pp S69-71). A single dose trial of nebulised lergic bronchopulmonary aspergillosis, many of antibiotic is advisable with measurement of whom had evidence of bronchiectasis (D C PEFR and spirometric parameters before, imCurrie, personal communication).
mediately after, and 15 minutes after nebulisation.
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It is logical for nebulised antibiotics to be preceded by self-physiotherapy and, if neces-   The main potential problems with nebulised sary, bronchodilators. Precise recommendations with respect to use of outflow filters or antimicrobial therapy are bronchospasm and/ or chest tightness. These are especially relevant venting out of the window are not possible.
Further research is required in this area. The in a disease characterised by increased bronchial hyperreactivity and asthma. The char-approach outlined in the paper on cystic fibrosis is one possible strategy. However, it may be acteristics of the final drug solution, in particular isotonicity, and the nebuliser system possible to use filters for longer and it may be helpful to use them at home as well as in are important. The clinical relevance and frequency of the selection of antibiotic resistant hospital. organisms are unknown. The frequent use of antibiotics orally and intravenously in patients with purulent sputum complicates the as- Treatment must be carefully evaluated in each sessment of the balance between risk and benefit of the nebulised route for antibiotics.
patient. Specific questions should be answered. Is the purulent sputum volume between exNebulised colistin, 17 aminoglycosides, antipseudomonal penicillins, and third generation acerbations reduced after starting nebulised
